Drug Profile

Research programme: FAP targeting theranostics - Telix Pharmaceuticals

Latest Information Update: 05 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Johannes Gutenberg-University Mainz
Developer Telix Pharmaceuticals
Class Antineoplastics; Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Nov 2024 Telix Pharmaceuticals in-licenses FAP targeting radiopharmaceuticals from Johannes Gutenberg-University Mainz
18 Nov 2024 Early research in Bladder cancer (Diagnosis) in Australia (unspecified route)
18 Nov 2024 Early research in Bladder cancer in Australia (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com